Search the Newsreel

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat …

Milestone’s FDA Win Now Faces A Tougher Test: Sales

Milestone Pharmaceuticals (NASDAQ: MIST) recently gained FDA approval for its lead product, CARDAMYST™ (etripamil) nasal spray, for PSVT. However, the company now faces the challenge of commercializing the product, with early sales and market sentiment being mixed. The success of CARDAMYST depends heavily on …

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story

Regeneron Pharmaceuticals is facing securities class action lawsuits concerning alleged misleading statements about its Phase III Fianlimab-Libtayo trial. These lawsuits, focusing on disclosure practices regarding trial delays and failure, could influence investor perception of Regeneron's pipeline-driven strategy, especially as the company advances new programs …

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with …

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

NRx Pharmaceuticals (NASDAQ:NRXP) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $34.50. Despite this, the company recently missed its quarterly earnings and revenue estimates. Hedge funds and institutional investors hold 4.27% of the stock.

Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall

Vertex Pharmaceuticals (VRTX) has seen strong multi-year performance, with a 158.2% return over the past five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. The stock trades at 29.1x earnings, slightly above Simply Wall St's fair P/E estimate …

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Wall Street Zen has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from a "buy" to a "strong-buy" rating. This upgrade follows Regeneron's strong quarterly earnings, where it surpassed analyst expectations for both EPS and revenue. Despite positive news regarding pipeline expansion and collaborations, the company faces risks …

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from a "Sell" to a "Hold" rating, though overall analyst opinions remain mixed, with MarketBeat reporting a "Moderate Buy" consensus. The company recently exceeded earnings estimates, reporting a quarterly EPS of negative $0.07 against an expected …

Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121

Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen

Wall Street Zen upgraded Eledon Pharmaceuticals (NASDAQ:ELDN) from "strong sell" to "sell," though the broader analyst consensus remains "Hold" with a $9.67 target price. The company reported a quarterly loss of $0.27 per share, missing estimates, and its shares opened at $3.54. Institutional investors …

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen has upgraded Oramed Pharmaceuticals (NASDAQ:ORMP) from a "hold" to a "buy" rating, though MarketBeat's overall analyst rating for the company remains "Hold." Oramed Pharmaceuticals opened at $4.48, with a market capitalization of $186.35 million. The company recently reported a quarterly loss …

LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded LB Pharmaceuticals (NASDAQ:LBRX) from "hold" to "sell" despite a broader analyst consensus of "Moderate Buy" with an average price target of $47.75. The company recently reported a quarterly loss of $1.71 per share, missing consensus estimates, and analysts anticipate a …

NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded NRx Pharmaceuticals (NASDAQ:NRXP) from a "hold" to a "sell" rating, despite other analysts maintaining a "Moderate Buy" consensus with an average price target of $34.50. The company's stock opened at $3.27, reflecting a 2.1% drop, and recently reported a …

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Verrica Pharmaceuticals (NASDAQ:VRCA) from a "sell" to a "strong sell" rating. Despite this, the stock has a consensus "Hold" rating and an average target price of $14.50 from other analysts. The company recently reported a quarterly loss of $0.41 per …

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

BioCryst Pharmaceuticals reported a significant profit swing in Q2 2026, with revenue of US$218.25 million and net income of US$78.4 million, prompting a raised full-year revenue outlook to US$690 million–US$715 million. Despite this strong quarter, the company still faces a substantial year-to-date net loss …

Aarey Drugs & Pharmaceuticals standalone net profit declines 25.55% in the June 2026 quarter

(RIGL) Price Dynamics and Execution-Aware Positioning

This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) focusing on its price dynamics and execution-aware positioning based on AI models. It identifies strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels above the current price, and outlines specific …

ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside

The average 12-month price target for ACADIA Pharmaceuticals Inc. (ACAD) stock has been lowered from $33.65 to $33.05 by 19 analysts, with a range of $17 to $41 per share. This new target suggests a potential 17% upside based on the August 14 closing …

Hansoh Pharmaceutical Group Stock Sheds 1.7% in Hong Kong

Kiniksa Pharmaceuticals International, plc Class A Revenue Breakdown – BIVA:KNSA/N

Kiniksa Pharmaceuticals International, plc (BIVA:KNSA/N) generated 12.21 billion MXN in revenue last year, primarily from its Therapeutic Medicines segment. The United States was the largest contributor to this revenue, accounting for 12.20 billion MXN. This represents an increase from the previous year's segment revenue …

Quoin Pharmaceuticals | 10-Q: Quarterly report

This document is a quarterly report (10-Q) filed by Quoin Pharmaceuticals. It contains financial statements and other important disclosures required by the Securities and Exchange Commission for the reporting period.

Lexicon Pharmaceuticals (LXRX) Completes Phase III Enrollment, Is The 38% Undervaluation Case Convincing?

Lexicon Pharmaceuticals (LXRX) has completed enrollment in its Phase III SONATA HCM trial for sotagliflozin, with positive momentum from regulatory updates and partner collaborations. The company is considered 38% undervalued by some narratives, trading at $2.34 against a fair value of $3.77 per share, …

Nicola Greenway (TAK) plans sale of 12,980 Takeda ADSs after RSU vesting

Nicola Greenway has filed a notice to sell 12,980 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited, derived from vested Restricted Stock Unit Awards. The planned sale is scheduled for August 14, 2026, through Interactive Brokers LLC. This follows previous sales on August …

Syndax Pharmaceuticals (SNDX) Moved, What Is Behind The Fresh Attention?

Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals

Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals, Inc., had 2,500 Performance Share Units (PSUs) vest on August 12, 2026. Following the vesting, 1,158 shares were withheld by the company at $46.57 per share to cover tax …

InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares

Ikarian Capital, LLC and Neil Shahrestani have jointly reported a 4.2% beneficial ownership stake in InMed Pharmaceuticals Inc. (INM), totaling 137,634 common shares. This ownership, held through Ikarian Healthcare Master Fund, L.P. and separately managed accounts, is based on 3,314,063 common shares outstanding as …

Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary

Processa Pharmaceuticals (PCSA) reported a net loss of $(3.27M) and diluted EPS of $(1.19) for the third quarter of 2026, showing an improvement from the previous year, with no product revenue. The company recently acquired Vidya, securing $200M in funding to advance new clinical …

NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results, Misses Estimates By $0.35 EPS

NRx Pharmaceuticals (NASDAQ:NRXP) reported quarterly earnings of $(0.44) EPS, significantly missing the consensus estimate of $(0.09) by $0.35. Following the announcement, shares of NRXP fell 2.1% to $3.27. Despite the earnings miss, analysts maintain a "Moderate Buy" rating with an average price target of …

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’

Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock

PMV Pharmaceuticals (NASDAQ:PMVP) Posts Earnings Results, Beats Expectations By $0.05 EPS

PMV Pharmaceuticals (NASDAQ:PMVP) reported a quarterly loss of $0.34 per share, beating analyst expectations by $0.05. Following the announcement, the stock rose 3.7% to $1.26. Analysts maintain a "Moderate Buy" rating with a $4.00 consensus price target, despite Oppenheimer lowering its target to $5.00.

Is Amylyx Pharmaceuticals (AMLX) A Bargain Following Its Q2 Loss Update?